Method and use of necrostatina - 1 for the treatment of axonal Degeneration induced by acute and chronic injury

摘要

The operation of the central and peripheral nervous systems is based on the electronic pulse drive between the nervous systems. This driving is done through neurodynamics (potential effects), which range from the dendritas and the nervous system to the axonales terminals. At these axonnel terminals, pulses (synapses) are transmitted through peripheral nerves or other ejaculatory cells (muscle fibers, secret cells).Page: 1 Therefore, the system is interconnected and delivers specific functions according to the requirements of the defendant. The integrity of these circuits is essential for the performance of their functions. Any degradation stimulus, whether physical, chemical, biological or radiation, will change their integrity, resulting in loss of function or pathology. An axon segment, which makes maintaining neurological integrity a therapeutic goal. Requirement 1: method of treatment for patients with axial degeneration,It is characterized by intravenous and / or intraperitoneal and / or intraneural injections of a person with gangrene-1 or a salt acceptable to a derivative or drug thereof. Claim 2: a method for the treatment of patients with axial degeneration. As stated in claim 1, acceptable salts of patients with endocrine necrosis 1-1 or their derivatives or drugs are accepted within the acceptable dose range of injection and / or peritoneum Mg / kg body weight. Requirement 3: a method for treating patients with axial degeneration, according to requirement 1,It is characterized by an acceptable dose range of 0.1 to 100 mm of the nerve capacity treated by human neclostatina-1 patients or their derivatives or pharmaceutically acceptable salts. Requirement 6: a method for treating patients with axial degeneration, as described in requirement 5, characterized by acute neurological degeneration including ionizing radiation, mechanical damage and axonomic stimulation,Viral or bacterial infections and side effects of treatment. Requirement 8: the method of treating patients with axial decay, as required in Item 5, which is characterized by the fact that the axial decay caused by chronic neurological action includes stimulating factors: autoimmune diseases, such as multiple sclerosis (various forms);There are also sporadic genetic diseases, such as lateral amoebae sclerosis, Parkinson's disease, Alzheimer's disease, Charcot Marie Tooth disease and diabetic neuropathy. 113. Claim 11: use of neclostatina-1 and its derivatives, characterized by use in the production of a useful drug to treat axial degradation.